Asset Details
Do you wish to reserve the book?
Transportin1: a marker of FTLD-FUS
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Transportin1: a marker of FTLD-FUS
Do you wish to request the book?
Transportin1: a marker of FTLD-FUS
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Transportin1: a marker of FTLD-FUS
2011
Overview
The term frontotemporal lobar degeneration (FTLD) describes a group of disorders that are subdivided by the presence of one of a number of pathological proteins identified in the inclusion bodies observed post-mortem. The FUS variant is defined by the presence of the fused in sarcoma protein (FUS) in the pathological inclusions. However, similar to other FTLDs, the disease pathogenesis of FTLD-FUS remains largely poorly understood. Here we present data that the protein transportin1 (TRN1) is abundant in the FUS-positive inclusions. TRN1, the protein product of the TNP01 gene, is responsible for shuttling proteins containing an M9 nuclear localisation signal between the nuclear and cytoplasmic compartments. RNA interacting proteins, including FUS, have been implicated as targets of TRN1. Using TRN1 immunohistochemistry and Western blotting in this study, we investigated 13 cases of FTLD-FUS including 6 cases with neuronal intermediate filament inclusion disease (NIFID) and 7 atypical frontotemporal lobar degeneration with ubiquitinated inclusion (aFTLD-U) cases. The data from our immunohistochemical studies show that FUS-immunoreactive inclusions are also strongly labelled with the anti-TRN1 antibody and double-label immunofluorescence studies indicate good co-localisation between the FUS and TRN1 pathologies. Our biochemical investigations demonstrate that urea-soluble TRN1 is present in aFTLD-U and NIFID, but not in normal control brains. These findings implicate abnormalities of FUS transport in the pathogenesis of FTLD-FUS.
Publisher
Springer-Verlag,Springer Nature B.V
Subject
/ Aged
/ Amyotrophic lateral sclerosis
/ Autopsy
/ beta Karyopherins - metabolism
/ Brain
/ Cytomegalic inclusion disease
/ Dementia
/ Disease
/ Female
/ Frontotemporal Lobar Degeneration - diagnosis
/ Frontotemporal Lobar Degeneration - metabolism
/ Frontotemporal Lobar Degeneration - pathology
/ Humans
/ Inclusion Bodies - metabolism
/ Inclusion Bodies - pathology
/ Intranuclear Inclusion Bodies - metabolism
/ Intranuclear Inclusion Bodies - pathology
/ Male
/ Medicine
/ Proteins
/ RNA
/ Sarcoma
